MDT-AP-3295
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 3.4
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.657053307
- umap2_2d
- 0.226509419
- umap1_3d
- -0.934063305
- umap2_3d
- -3.012641073
- umap3_3d
- -1.05535476
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.390
- WNT_BETA_CATENIN_SIGNALING+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.310
- MTORC1_SIGNALING+0.300
- G2M_CHECKPOINT+0.290
- PROTEIN_SECRETION+0.260
- TGF_BETA_SIGNALING+0.220
- OXIDATIVE_PHOSPHORYLATION+0.190
- ANDROGEN_RESPONSE+0.170
Top 10 suppressed
- APICAL_SURFACE-0.330
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.270
- ALLOGRAFT_REJECTION-0.250
- HEDGEHOG_SIGNALING-0.250
- ANGIOGENESIS-0.220
- ESTROGEN_RESPONSE_LATE-0.220
- BILE_ACID_METABOLISM-0.210
- COAGULATION-0.210
- COMPLEMENT-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359438 | — | — | 0.820 |
| 2 | SRR13311164 | — | — | 0.808 |
| 3 | SAMN03290906 | — | — | 0.806 |
| 4 | SRR650156 | — | — | 0.805 |
| 5 | MNG666 | — | — | 0.788 |
| 6 | MDT-AP-2085 | Med | Medulloblastoma | 0.787 |
| 7 | MDT-AP-0167 | Med | Medulloblastoma | 0.787 |
| 8 | R143 | — | — | 0.787 |
| 9 | MDT-AP-3285 | Med | Medulloblastoma | 0.782 |
| 10 | MNG449 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |